Onset of effect, changes in airflow obstruction and lung volume, and health-related quality of life Improvements with benralizumab for patients with Severe Eosinophilic Asthma: Phase IIIb Randomized, Controlled Trial (SOLANA)
Author
dc.contributor.author
Panettieri, Reynold A.
Author
dc.contributor.author
Welte, Tobias
Author
dc.contributor.author
Shenoy, Kartik V.
Author
dc.contributor.author
Korn, Stephanie
Author
dc.contributor.author
Jandl, Margret
Author
dc.contributor.author
Kerwin, Edward M.
Author
dc.contributor.author
Feijoo Seoane, Rosa
Author
dc.contributor.author
Barker, Peter
Author
dc.contributor.author
Olsson, Richard F.
Author
dc.contributor.author
Martin, Ubaldo J.
Admission date
dc.date.accessioned
2020-05-08T14:18:39Z
Available date
dc.date.available
2020-05-08T14:18:39Z
Publication date
dc.date.issued
2020
Cita de ítem
dc.identifier.citation
Journal of Asthma and Allergy 2020:13 115–126
es_ES
Identifier
dc.identifier.other
10.2147/JAA.S240044
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/174581
Abstract
dc.description.abstract
Objective: In the SOLANA trial, we sought to physiologically characterize benralizumab's onset of effect and maintenance of that effect for patients with severe eosinophilic asthma.
Methods: SOLANA (NCT02869438) was a multicenter, randomized, double-blind, parallel-group, placebo-controlled, Phase IIIb study conducted at 49 centers in six countries (Chile, Germany, Hungary, the Philippines, South Korea, and the United States). Eligible patients with baseline blood eosinophil counts >= 300 cells/mu L were randomized to subcutaneous benralizumab (30 mg) or placebo administered at Days 0, 28, and 56. The primary endpoint was the average change from baseline in prebronchodilator forced expiratory volume in 1 s (pre-BD FEV1) during the Day 28.Day 84 period for benralizumab vs placebo. Secondary endpoints included patient-reported outcomes (PROs). A subset of patients participated in a whole-body plethysmography substudy. Safety was also assessed.
Results: In total, 233 patients were randomized to benralizumab (n=118) or placebo (n=115). Improvement from baseline in pre-BD FEV1 with benralizumab 30 mg was not statistically significant compared with placebo (least-squares mean change difference [95% confidence interval] 57 mL [-22 to 135]; p=0.16). Compared with placebo, benralizumab demonstrated early (Day 7) nonstatistically significant improvements in whole-body plethysmography assessments of hyperinflation and clinically meaningful improvements in PRO measures (Asthma Control Questionnaire 6 at Day 14 and St. George's Respiratory Questionnaire at Day 28), which were maintained over the treatment period. Benralizumab's safety profile was commensurate with previously reported studies.
Conclusion: The observed early changes in lung volume despite relatively small improvements in airflow obstruction suggest that the anti-inflammatory effect of benralizumab may be manifested as deflation over time for patients with hyperinflation, who potentially have a greater degree of airway remodeling. This early effect could partially explain the rapid PRO improvements observed for certain patients.
Onset of effect, changes in airflow obstruction and lung volume, and health-related quality of life Improvements with benralizumab for patients with Severe Eosinophilic Asthma: Phase IIIb Randomized, Controlled Trial (SOLANA)